Login to Your Account



Other News To Note


Thursday, May 5, 2011
Promedior Inc., of Malvern, Pa., reported that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 [PTX-2]) were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology in Ft. Lauderdale, Fla. In a poster, Promedior and collaborators from the Johns Hopkins University Wilmer Eye Institute highlighted the efficacy and utility of Pentraxin-2 in suppressing neovascularization in independent models of age-related macular degeneration and diabetic retinopathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription